Brought to you by 
Novexel gets €50mm in Series B money
27 Oct 2020
Executive Summary
Anti-infectives company Novexel (spun off from Sanofi-Aventis in 2004) received €50mm ($65mm) in its Series B financing led by new backer Edmond de Rothschild Investment Partners. Returning shareholders Atlas Venture, Sofinnova Partners, Abingworth, 3i, Novo AS, and BIT were joined by new investors Goldman Sachs, NeoMed, and NIF SMBC. A representative from Edmond de Rothschild will take a seat on Novexel's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novexel gets €50mm in Series B money
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice